Ayoubi Riham, Alende Charles, Fotouhi Maryam, Ruíz Moleón Vera, González Bolívar Sara, Southern Kathleen, Laflamme Carl
Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, H3A 2B4, Canada.
F1000Res. 2024 Sep 13;13:1055. doi: 10.12688/f1000research.155928.1. eCollection 2024.
CSNK1A1 is a key regulator of various signalling pathways, including the Wnt/β-catenin pathway. Playing a central role in cellular function and disease pathology, CSNK1A1 has emerged as an attractive protein target for therapeutic development. In this study we characterize ten CSNK1A1 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. This study is part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While the use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.
酪蛋白激酶1A1(CSNK1A1)是多种信号通路的关键调节因子,包括Wnt/β-连环蛋白通路。CSNK1A1在细胞功能和疾病病理中发挥核心作用,已成为治疗开发中一个有吸引力的蛋白质靶点。在本研究中,我们使用标准化实验方案,通过比较基因敲除细胞系和同基因亲本对照中的检测结果,对用于蛋白质印迹、免疫沉淀和免疫荧光的十种CSNK1A1商业抗体进行了表征。本研究是一项更大的合作计划的一部分,该计划旨在通过对人源蛋白质的市售抗体进行表征,并将结果公开作为科学界的资源,来解决抗体可重复性问题。虽然各实验室使用的抗体和方案有所不同,但我们鼓励读者将本报告作为指南,为其特定需求选择最合适的抗体。